Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Post by taylor1988on Nov 29, 2011 6:10am
425 Views
Post# 19273455

9-10

9-10Again, why do we need 9 - 10 g/t au when Kinross went into production at its Nixon Fork Mine with grades of 0.4 to 0.6 g/t gold at gold prices of $800 / oz and Brewery Creek is averaging 1.5 g/t au + with high-grade showings of 74 m @ 7.08 and a thick showing at Schooner I believe of 191 m @ 1.46 grams per tonne gold... with gold at $1,700 / oz. Like Scottie mentioned Victoria Gold's Eagle Gold Mine will go into production at lesser grades than Brewery Creek and that's just one property of GPD'. Royalties will start coming in beginning of 2013' which is just enough to ensure we most likely won't need to finance again until much higher levels with production coming after royalties. 9 - 10 g/t au gold? Why? If our results are in line with KAM' for the most part then wouldn't KAM have stopped drilling and given up at this point given the facts results of 1.0 - 2.0 g/t au are irrelevant in a market that needs 9 - 10 g/t au. Even ATC is hardly near those grades.. bottom line is GPD drills year roud while the other Yukon companies get put to rest for 6 months. KAM I could look at placing stink bids but at the end of the day what catalysts are there for the next 6 months? GPD, VIT is the only logical Yukon play with the other Yukon juniors trading at their respective market caps imo.
Bullboard Posts